ArticleVaccines2022

COVID-19 Vaccine Booster Dose Willingness among Patients with Inflammatory Bowel Disease on Infliximab and Vedolizumab: A Cross-Sectional Study.

Mohammad Shehab et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.